Samsung Biologics Co.,Ltd. (207940.KS)
- Previous Close
1,005,000.00 - Open
996,000.00 - Bid 998,000.00 x --
- Ask 1,001,000.00 x --
- Day's Range
995,000.00 - 1,006,000.00 - 52 Week Range
721,000.00 - 1,209,000.00 - Volume
38,117 - Avg. Volume
69,211 - Market Cap (intraday)
71.032T - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jul 22, 2025 - Jul 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,318,304.38
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
samsungbiologics.comRecent News: 207940.KS
View MorePerformance Overview: 207940.KS
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 207940.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 207940.KS
View MoreValuation Measures
Market Cap
71.53T
Enterprise Value
71.68T
Trailing P/E
66.03
Forward P/E
49.02
PEG Ratio (5yr expected)
2.31
Price/Sales (ttm)
15.73
Price/Book (mrq)
6.56
Enterprise Value/Revenue
15.76
Enterprise Value/EBITDA
35.50
Financial Highlights
Profitability and Income Statement
Profit Margin
23.82%
Return on Assets (ttm)
4.94%
Return on Equity (ttm)
10.45%
Revenue (ttm)
4.55T
Net Income Avi to Common (ttm)
1.08T
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.33T
Total Debt/Equity (mrq)
13.63%
Levered Free Cash Flow (ttm)
55.87B